Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation

被引:8
|
作者
Vrachimis, A. [1 ]
Schober, O. [1 ]
Riemann, B. [1 ]
机构
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2012年 / 51卷 / 03期
关键词
Radioiodine; remnant ablation; thyroid hormone withdrawal; rhTSH; RECOMBINANT HUMAN THYROTROPIN; HORMONE WITHDRAWAL; FOLLOW-UP; CARCINOMA; THERAPY; HYPOTHYROIDISM; RISK; MANAGEMENT; RHTSH; COST;
D O I
10.3413/Nukmed-0432-11-10
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: Radioiodine remnant ablation (RRA) after (near-)total thyroidectomy (TE) is a key element in patients with differentiated thyroid cancer (DTC). The use of exogenous TSH stimulation (rhTSH) prior to RRA has shown promising results as compared to conventional thyroid hormone withdrawal (THW). As yet, the efficacy of RRA after brief THW and single rhTSH administration has not been assessed. Patients, methods: The study sample comprised 147 patients with DTC referred to our center between May 2008 and September 2010. All patients received TE with subsequent RRA. None of these 147 patients had evidence of distant metastasis. 93 patients had endogenous TSH stimulation 4-5 weeks after surgery (group I) and twenty-six received two rhTSH injections (group II). 28 patients were treated with a single rhTSH injection after a brief THW (group III). RRA-Efficacy was assessed three months after therapy by diagnostic whole-body scan and measurement of the tumour marker thyroglobulin (Tg) under TSH stimulation. Results: Three categories of success were defined for remnant ablation. Based on the definition of successful remnant ablation no visible uptake and a Tg <= 2.0 ng/ml (category 1) was seen in 62/93 patients in group I, in 17/26 patients in group II (p = n.s.) and in 12/28 patients in group III (p < 0.05). Visible radioiodine uptake and a Tg <= 2.0 ng/ml (category 2) was seen in 16/28 patients of group III and thus significantly more frequent than in group I (28/93 patients) (p < 0.01). However, patients in group III (16/28 patients) and group II (8/26 patients) showed no significant difference in this category (p = n.s.). Visible radioiodine uptake and a Tg > 2.0 ng/ml (category 3) was found in 3/93 patients in group I and 1/26 patients in group II but in no patient in group III. Conclusion:The third strategy of remnant ablation using a single injection of rhTSH after a brief THW period resulted in a significant higher rate of patients with residual uptake in the thyroid bed and a Tg level below 2 ng/ml three months after remnant ablation in comparison to THW. However, the overall efficacy of the third protocol was not significantly different as compared to two rhTSH injections. Under the aspect of the supply shortage of rhTSH the combined endogenous and exogenous TSH stimulation may be an attractive alternative for remnant ablation in differentiated thyroid cancer.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [1] Comparison between endogenous and exogenous TSH stimulation in the effectiveness of radioiodine ablation therapy in patients with Differentiated Thyroid Carcinoma
    Saraiva, T.
    Silva, R.
    Albuquerque, A.
    Costa, G.
    Pedroso de Lima, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S154 - S154
  • [2] Therapeutic efficacies of remnant ablation and radioiodine adjuvant therapy in differentiated thyroid cancer
    Liu, Yanlin
    Huang, Shuhui
    Li, Xiaohui
    Tian, Tian
    Huang, Rui
    ENDOCRINE, 2025, 87 (02) : 734 - 743
  • [3] Exogenous versus endogenous TSH Stimulation before Radioiodine Therapy
    不详
    ONKOLOGE, 2010, 16 (12): : 1203 - 1203
  • [4] Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma
    Long, Bin
    Li, Linfa
    Yao, Lifang
    Chen, Shoucong
    Yi, Heqing
    Ye, Xuemei
    Xu, Dong
    Wu, Peng
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (08) : 244 - 247
  • [5] Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros
    Ain, Kenneth B.
    ENDOCRINE, 2015, 50 (01) : 61 - 66
  • [6] Radioiodine Remnant Ablation for Differentiated Thyroid Cancer A Systematic Review and Meta-analysis
    James, Danielle L.
    Ryan, Eanna J.
    Davey, Matthew G.
    Quinn, Alanna Jane
    Heath, David P.
    Garry, Stephen James
    Boland, Michael R.
    Young, Orla
    Lowery, Aoife J.
    Kerin, Michael J.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2021, 147 (06) : 544 - 552
  • [7] Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros
    Kenneth B. Ain
    Endocrine, 2015, 50 : 61 - 66
  • [8] Low-activity Radioiodine for Remnant Ablation after Surgery for Differentiated Thyroid Cancer-Initial Experience
    Sobral Violante, L. C.
    Teixeira, J.
    Sampaio, I.
    Martins, R.
    Couto, J.
    Fonseca, A.
    Costa, L.
    Lopes, F.
    Soares, O.
    Duarte, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S503 - S504
  • [9] Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy ina real life scenario
    Campenni, A.
    Giovanella, L.
    Pignata, S.
    Mure, M.
    Siracusa, M.
    Cosentino, F.
    Sturiale, L.
    Coppolino, P.
    Ruggeri, M.
    Baldari, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S325 - S326
  • [10] Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario
    Campenni, Alfredo
    Giovanella, Luca
    Pignata, Salvatore A.
    Violi, Maria A.
    Siracusa, Massimiliano
    Alibrandi, Angela
    Moleti, Mariacarla
    Amato, Ernesto
    Ruggeri, Rosaria M.
    Vermiglio, Francesco
    Baldari, Sergio
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (11) : 1100 - 1106